A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Nikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Dimopoulos, Margarita Kulakova, Annette Lam, Mahmoud Hashim, Jianming He, Bart Heeg, Jon Ukropec, Jessica Vermeulen, Sarah Cote, Nizar Bahlis
The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles published up to 8 June 2019, with no date limit on the indexed database.
Clinical end points stratified by MRD status (positive or negative) were extracted, including hazard ratios (HRs) on PFS and OS, P values, and confidence intervals (CIs). HRs were estimated based on reconstructed patient-level data from published Kaplan-Meier curves. Forty-four eligible studies with PFS data from 8098 patients, and 23 studies with OS data from 4297 patients were identified to assess the association between MRD status and survival outcomes. Compared with MRD positivity, achieving MRD negativity improved PFS (HR, 0.33; 95% CI, 0.29-0.37; P < .001) and OS (HR, 0.45; 95% CI, 0.39-0.51; P < .001).
MRD negativity was associated with significantly improved survival outcomes regardless of disease setting (newly diagnosed or relapsed/refractory MM), MRD sensitivity thresholds, cytogenetic risk, method of MRD assessment, depth of clinical response at the time of MRD measurement, and MRD assessment premaintenance and 12 months after start of maintenance therapy.
The strong prognostic value of MRD negativity and its association with favorable outcomes in various disease and treatment settings sets the stage to adopt MRD as a treatment end point, including development of therapeutic strategies. This large meta-analysis confirms the utility of MRD as a relevant surrogate for PFS and OS in MM.
CITA DEL ARTÍCULO Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.